ACP-MLC: A two-level prediction engine for identification of anticancer peptides and multi-label classification of their functional types. (May 2023)
- Record Type:
- Journal Article
- Title:
- ACP-MLC: A two-level prediction engine for identification of anticancer peptides and multi-label classification of their functional types. (May 2023)
- Main Title:
- ACP-MLC: A two-level prediction engine for identification of anticancer peptides and multi-label classification of their functional types
- Authors:
- Deng, Hua
Ding, Meng
Wang, Yimeng
Li, Weihua
Liu, Guixia
Tang, Yun - Abstract:
- Abstract: Anticancer peptides (ACPs), a series of short bioactive peptides, are promising candidates in fighting against cancer due to their high activity, low toxicity, and not likely cause drug resistance. The accurate identification of ACPs and classification of their functional types is of great importance for investigating their mechanisms of action and developing peptide-based anticancer therapies. Here, we provided a computational tool, called ACP-MLC, to address binary classification and multi-label classification of ACPs for a given peptide sequence. Briefly, ACP-MLC is a two-level prediction engine, in which the 1st-level model predicts whether a query sequence is an ACP or not by random forest algorithm, and the 2nd-level model predicts which tissue types the sequence might target by the binary relevance algorithm. Development and evaluation by high-quality datasets, our ACP-MLC yielded an area under the receiver operating characteristic curve (AUC) of 0.888 on the independent test set for the 1st-level prediction, and obtained 0.157 hamming loss, 0.577 subset accuracy, 0.802 F1-scoremacro, and 0.826 F1-scoremicro on the independent test set for the 2nd-level prediction. A systematic comparison demonstrated that ACP-MLC outperformed existing binary classifiers and other multi-label learning classifiers for ACP prediction. Finally, we interpreted the important features of ACP-MLC by the SHAP method. User-friendly software and the datasets are available atAbstract: Anticancer peptides (ACPs), a series of short bioactive peptides, are promising candidates in fighting against cancer due to their high activity, low toxicity, and not likely cause drug resistance. The accurate identification of ACPs and classification of their functional types is of great importance for investigating their mechanisms of action and developing peptide-based anticancer therapies. Here, we provided a computational tool, called ACP-MLC, to address binary classification and multi-label classification of ACPs for a given peptide sequence. Briefly, ACP-MLC is a two-level prediction engine, in which the 1st-level model predicts whether a query sequence is an ACP or not by random forest algorithm, and the 2nd-level model predicts which tissue types the sequence might target by the binary relevance algorithm. Development and evaluation by high-quality datasets, our ACP-MLC yielded an area under the receiver operating characteristic curve (AUC) of 0.888 on the independent test set for the 1st-level prediction, and obtained 0.157 hamming loss, 0.577 subset accuracy, 0.802 F1-scoremacro, and 0.826 F1-scoremicro on the independent test set for the 2nd-level prediction. A systematic comparison demonstrated that ACP-MLC outperformed existing binary classifiers and other multi-label learning classifiers for ACP prediction. Finally, we interpreted the important features of ACP-MLC by the SHAP method. User-friendly software and the datasets are available at https://github.com/Nicole-DH/ACP-MLC . We believe that the ACP-MLC would be a powerful tool in ACP discovery. Graphical abstract: Image 1 Highlights: ACP-MLC is a two-level ACP prediction engine trained on reliable datasets. ACP-MLC can not only distinguish ACPs but also classify their functional types. It achieved comparable performance with existing methods in binary classification. SHAP method was applied to help intuitively judge the properties of the peptides. ACP-MLC is available as standalone software. … (more)
- Is Part Of:
- Computers in biology and medicine. Volume 158(2023)
- Journal:
- Computers in biology and medicine
- Issue:
- Volume 158(2023)
- Issue Display:
- Volume 158, Issue 2023 (2023)
- Year:
- 2023
- Volume:
- 158
- Issue:
- 2023
- Issue Sort Value:
- 2023-0158-2023-0000
- Page Start:
- Page End:
- Publication Date:
- 2023-05
- Subjects:
- Anticancer peptides -- Machine learning -- Multi-label learning -- Sequence analysis -- Feature selection
Medicine -- Data processing -- Periodicals
Biology -- Data processing -- Periodicals
610.285 - Journal URLs:
- http://www.sciencedirect.com/science/journal/00104825/ ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.compbiomed.2023.106844 ↗
- Languages:
- English
- ISSNs:
- 0010-4825
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3394.880000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 26899.xml